"Administration, Topical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example.
| Descriptor ID |
D000287
|
| MeSH Number(s) |
E02.319.267.120
|
| Concept/Terms |
Administration, Topical- Administration, Topical
- Drug Administration, Topical
- Topical Drug Administration
- Topical Administration
- Administrations, Topical
- Topical Administrations
- Administration, Topical Drug
- Administrations, Topical Drug
- Drug Administrations, Topical
- Topical Drug Administrations
|
Below are MeSH descriptors whose meaning is more general than "Administration, Topical".
Below are MeSH descriptors whose meaning is more specific than "Administration, Topical".
This graph shows the total number of publications written about "Administration, Topical" by people in this website by year, and whether "Administration, Topical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 3 | 3 |
| 1994 | 0 | 3 | 3 |
| 1995 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Administration, Topical" by people in Profiles.
-
Zhang H, Wang P, Wang X, Shi L, Fan Z, Zhang G, Yang D, Bahavar CF, Zhou F, Chen WR, Wang X. Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice. Technol Cancer Res Treat. 2018 01 01; 17:1533033818785275.
-
Yang X, Trinh HM, Agrahari V, Sheng Y, Pal D, Mitra AK. Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate. AAPS PharmSciTech. 2016 Apr; 17(2):294-306.
-
Bakhsheshian J, Dahdaleh NS, Smith ZA. Letter to the Editor concerning "Intrawound vancomycin to prevent infections after spine surgery: a systematic review and meta-analysis" by Evaniew N, Khan M, Drew B, Peterson D, Bhandari M, Ghert M (2014) Eur Spine J; DOI 10.1007/s00586-014-3357-0. Eur Spine J. 2014 Sep; 23(9):2014-5.
-
Sheets KG, Jun B, Zhou Y, Zhu M, Petasis NA, Gordon WC, Bazan NG. Microglial ramification and redistribution concomitant with the attenuation of choroidal neovascularization by neuroprotectin D1. Mol Vis. 2013; 19:1747-59.
-
Dyer RK, Weinstock MA, Cohen TS, Rizzo AE, Bingham SF. Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial. J Invest Dermatol. 2012 Nov; 132(11):2544-51.
-
Sainathan SK, Bishnupuri KS, Aden K, Luo Q, Houchen CW, Anant S, Dieckgraefe BK. Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis. Inflamm Bowel Dis. 2012 May; 18(5):955-67.
-
Guess SM, Butt AL, Neely SB, Wild RC, Chou AF, Chodosh J. Dissemination of knowledge from randomized clinical trials for herpes simplex virus keratitis. Arch Ophthalmol. 2010 Dec; 128(12):1624-5.
-
Chen NF, Smith ZA, Stiner E, Armin S, Sheikh H, Khoo LT. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion. J Neurosurg Spine. 2010 Jan; 12(1):40-6.
-
Babizhayev MA, Micans P, Guiotto A, Kasus-Jacobi A. N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients. Am J Ther. 2009 Nov-Dec; 16(6):517-33.
-
Babizhayev MA, Kasus-Jacobi A. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr Clin Pharmacol. 2009 Jan; 4(1):4-37.